Table I.
Selected drugs with epigenetic targets in the preclinical and clinical development of leukemia.
| Drug target | Drug | Chemical class | Study in leukemia | Clinical trials |
|---|---|---|---|---|
| DNMT inhibitor | Azacitidine | Nucleoside analog | ALL, AML, CML | + |
| DNMT inhibitor | Decitabine (DAC) | Nucleoside analog | ALL, AML, CML | + |
| HDAC inhibitor | Valproic acid (VPA) | Short-chain fatty acid | AML, CLL, CML | + |
| HDAC inhibitor | Trichostatin A (TSA) | Hydroxamic acid | Preclinical trials | N/A |
| HDAC inhibitor | Panobinostat (LBH589) | Hydroxamic acid | ALL, AML | + |
| HDAC inhibitor | Depsipeptide (FR901228/FK228) | Cyclic tetrapeptide | AML | + |
| HDAC inhibitor | Entinostat (MS275/SNDX-275) | Benzamide | ALL, AML | + |
| HDAC inhibitor | MGCD0103 | Benzamide | AML, CLL | + |
AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia. DNMT, DNA methyltransferase; HDAC, histone deactylase.